{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aclaris Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ACRS"},"Address":{"label":"Address","value":"640 LEE ROAD SUITE 200, WAYNE, Pennsylvania, 19087, United States"},"Phone":{"label":"Phone","value":"+1 484 324-7933"},"Industry":{"label":"Industry","value":"Biotechnology: Commercial Physical &amp; Biological Resarch"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777."},"CompanyUrl":{"label":"Company Url","value":"https://www.aclaristx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Douglas J. Manion","title":"President, Chief Executive Officer &amp; Director"},{"name":"Joseph B. Monahan","title":"Chief Scientific Officer"},{"name":"Monica Salamea","title":"Vice President-Clinical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}